miR‐545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG‐I
Bin SongDepartment of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, ChinaWeiping JiDepartment of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, ChinaShiwei GuoDepartment of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, ChinaAn‐An LiuDepartment of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, ChinaWei JingDepartment of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, ChinaChenghao ShaoDepartment of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, ChinaGang LiDepartment of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, ChinaGang JinDepartment of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
2014en
ABI
Аннотация
Pancreatic ductal adenocarcinoma (PDAC) ranks fourth on the list of cancer‐related causes of death. Deregulation or dysfunction of miRNAs contribute to cancer development. In this study, we found that low miR‐545 level and high RIG‐I protein in PDAC tissues were both correlated with low survival rate. MiR‐545 up‐regulation inhibited PDAC cell lines growth and vice versa. 3′UTR of RIG‐I was targeted by miR‐545. Thus we concluded that low miR‐545 levels in PDAC promote tumor cells growth, and this is associated with reduced survival in PDAC patients. MiR‐545 exerts its effects by directly targeting RIG‐1.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0